GlassScriptPhysician profile
Nicholas Zelie
NPI 1437675329
$4,456.57
in general payments reported to CMS, 2019-2025
13 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 91% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.44 · 2022: $166 · 2023: $129 · 2024: $2,986 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948 · Consulting Fee: $1,900 · Education: $252 · Travel and Lodging: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.68 |
| Consulting Fee | $1,900.00 |
| Education | $251.98 |
| Travel and Lodging | $100.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,550.89 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $565.04 | 2021-2025 | Nemluvio |
| Janssen Biotech, INC. | $458.32 | 2023-2025 | Tremfya |
| Dermavant Sciences, INC. | $203.20 | 2023-2024 | Vtama |
| Abbvie INC. | $153.60 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Dupixent |
| Organon LLC | $101.84 | 2025 | Vtama |
| Leo Pharma INC. | $100.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.89 | 2024 | Sotyktu |
| Lilly USA, LLC | $38.57 | 2024 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $35.42 | 2023-2024 | |
| Amgen INC. | $24.46 | 2023 | Otezla |
| Sun Pharmaceutical Industries INC. | $19.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Zelie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.